Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.

Details

Serval ID
serval:BIB_FF92BBB469D2
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.
Journal
Oncology research and treatment
Author(s)
Siebenhüner A., De Dosso S., Meisel A., Wagner A.D., Borner M.
ISSN
2296-5262 (Electronic)
ISSN-L
2296-5270
Publication state
Published
Issued date
2020
Peer-reviewed
Oui
Volume
43
Number
5
Pages
237-244
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Metastatic colorectal carcinoma (mCRC) is one of the most prevalent types of cancer worldwide. After tumor progression with first- and second-line treatment, trifluridine (FTD) and tipiracil (TPI) has been shown to be a treatment option.
Data from a pivotal phase 3 trial (RECOURSE) and an ongoing phase 3b trial (PRECONNECT) have shown that, in mCRC patients who experienced disease progression after 2 lines of standard therapy, treatment with FTD/TPI is safe and efficacious. Other third-line options include regorafenib, rechallenge with previous treatment lines or personalized approaches based on comprehensive molecular profiling. Randomized trials or sequential studies aiming for the right treatment sequence or predefined subtypes for FTD/TPI or regorafenib as well for rechallenge are missing. However, FTD/TPI as well as regorafenib are recommended by the current ESMO, German S3, and National Comprehensive Cancer Network (NCCN) guidelines in the same situation, thus offering physicians a number of alternatives for the treatment of mCRC patients after the second progression. Key Message: This narrative review summarizes published data and their impact for FTD/TPI as well for regorafenib and rechallenge chemotherapy in clinical practice settings of refractory situations of colorectal cancer.
Keywords
Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Clinical Trials, Phase III as Topic, Colorectal Neoplasms/drug therapy, Colorectal Neoplasms/mortality, Colorectal Neoplasms/pathology, Disease Progression, Drug Combinations, Humans, Neoplasm Metastasis, Phenylurea Compounds/therapeutic use, Pyridines/therapeutic use, Pyrrolidines/therapeutic use, Survival Rate, Switzerland, Treatment Outcome, Trifluridine/therapeutic use, Uracil/analogs & derivatives, Uracil/therapeutic use, Lonsurf, Rechallenge, Refractory colorectal cancer, Regorafenib, Second progression, Tas-102, Trifluridine-tipiracil
Pubmed
Web of science
Open Access
Yes
Create date
10/03/2020 15:28
Last modification date
26/11/2020 6:26
Usage data